Compare Recursion Pharmaceuticals Inc (RXRX) vs iShares TIPS Bond ETF (TIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs iShares TIPS Bond ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B), while iShares TIPS Bond ETF trades at $104.42 (market cap $14.17B). The key difference: iShares TIPS Bond ETF is far larger — about 6.6× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and iShares TIPS Bond ETF for 62 Days on average.
| RXRX | TIP | |
|---|---|---|
Market Cap | $2.14B | $14.17B |
Volume | 30,789,535 | 1,780,688 |
Sector | Health | Fixed Income |
52-Week High | $6.79 | $112.20 |
52-Week Low | $2.84 | $103.98 |
Typical Hold Time | 23 Days | 62 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
TIP trades at $104.42, up 0.17% today, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. Key support is at $104 and resistance at $105. Recent news highlights institutional accumulation, with Envestnet increasing its stake by 3.5% in the latest quarter. The ETF remains in focus amid a volatile bond market environment.
The outlook is cautious amid rising Treasury yields and inflation concerns. Opportunities include defensive positioning appeal and a scheduled dividend payment in August 2026. Risks involve interest rate sensitivity and broader market volatility driven by geopolitical and economic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About iShares TIPS Bond ETF
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →
